Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STALWART: Proleukin with or without HAART in HIV-1 Infection
NCT00110812Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2005
- Primary completion
- Feb 2011
- Modality
- Cytokines & Interferons
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of aldesleukin in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Mean Change in CD4+ T Lymphocyte Count at 32 weeks. Started Sep 2005; status: completed.
02
Drugs
aldesleukin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00110812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110812.